Eli Lilly (LLY) shares hit a record high Tuesday after IPO stock Kailera Therapeutics posted lackluster test results for its weight-loss pill. Kailera’s partner, Hengrui Pharma, ran two studies in patients in China. But the results seemingly paled in comparison to what Eli Lilly’s Foundayo and Novo Nordisk’s (NVO) Wegovy pill have shown in their own clinical tests. In response,…
Copyright ©2026 Investor’s Business Daily, LLC. All rights reserved. 87990cbe856818d5eddac44c7b1cdeb8
